A 1-year randomized controlled trial in 130 Alzheimer's patients found that ALCAR treatment (dosage not specified in abstract) resulted in slower rates of deterioration across 13 of 14 outcome measures, with statistical significance achieved for memory, intelligence, attention, and functional scales
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Originally developed for diabetes management, these drugs, popularized under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, are redefining how we think about obesity, metabolic health, and even chronic disease prevention
Eli Lilly has sued companies in 34 states on similar claims, alleging they illegally mass-produced "knock-offs" of its GLP-1 drugs, Mounjaro and Zepbound